Philipp Berning

Hematology Oncology
1275 York Ave
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications

Preclinical discovery and clinical development of glofitamab in relapsed/ refractory large B-cell lymphomas.

Preclinical discovery and clinical development of glofitamab in relapsed/ refractory large B-cell lymphomas.

Journal: Expert opinion on drug discovery
Published: June 08, 2026

Pre-CAR-T B-cell-directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis.

Pre-CAR-T B-cell-directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis.

Journal: Bone marrow transplantation
Published: May 20, 2026

Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party.

Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party.

Journal: Journal of hematology & oncology
Published: December 27, 2025

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis.

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis.

Journal: Blood cancer journal
Published: November 08, 2025

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Haematologica
Published: October 17, 2025

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Haematologica
Published: October 17, 2025

Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemia.

Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemia.

Journal: Leukemia research
Published: October 06, 2025

Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working Party.

Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working Party.

Journal: HemaSphere
Published: October 02, 2025

Longitudinal analysis of usage and public awareness of tyrosine kinase inhibitors for CML.

Longitudinal analysis of usage and public awareness of tyrosine kinase inhibitors for CML.

Journal: Frontiers in oncology
Published: September 23, 2025

Low cardiovascular event rates in patients treated with CAR T-cells: Real-world outcomes from two independent cohorts.

Low cardiovascular event rates in patients treated with CAR T-cells: Real-world outcomes from two independent cohorts.

Journal: ESC heart failure
Published: August 30, 2025

Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.

Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.

Journal: Blood neoplasia
Published: June 09, 2025

Title: Prescription Trends of Hydrochlorothiazide vs. Chlorthalidone in the United States (2019-2024).

Title: Prescription Trends of Hydrochlorothiazide vs. Chlorthalidone in the United States (2019-2024).

Journal: American journal of hypertension
Published: May 30, 2025
Showing 1-12 of 50

Last Updated: 09/26/2026